Answer
Leucopenia was reported in 20% of 109 patients with cutaneous T-cell lymphoma receiving Targretin (bexarotene) at the recommended initial dose of 300 mg/m²/day in clinical trials.
Sources for this answer
- Targretin CapsulesH.A.C. PHARMA · emc · SmPC §4.8 Undesirable effects · Version 9Document updated
Sources checked